|
Market Closed -
Euronext Bruxelles
23:55:00 05/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 200.90 EUR | -1.66% |
|
-6.30% | -15.80% |
| 09-30 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 09-29 | UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session | CI |
| Market Cap | 38.3B 42.98B 35.71B 32.5B 61.27B 4,140B 61.64B 431B 168B 2,111B 161B 158B 6,786B | P/E 2026 * |
20.1x | P/E 2027 * | 16.7x |
|---|---|---|---|---|---|
| Enterprise Value | 38.72B 43.44B 36.09B 32.85B 61.93B 4,185B 62.3B 436B 169B 2,134B 163B 160B 6,859B | EV / Sales 2026 * |
4.47x | EV / Sales 2027 * | 3.81x |
| Free-Float |
61.59% | Yield 2026 * |
0.72% | Yield 2027 * | 0.75% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Bruxelles
| UCB | Real-time | |
CBOE
| UCB | Real-time | |
|
Tradegate
| UNC | Real-time | |
|
Xetra
| UNC | Delayed | |
|
Börse Stuttgart
| UNC | Delayed | |
|
OTC Markets
| UCBJF | Delayed | |
|
Boerse Muenchen
| UNC | Real-time | |
|
Deutsche Boerse AG
| UNC | Delayed | |
|
London S.E.
| 0NZT | Delayed | |
|
CBOE
| 0NZT | Real-time | |
|
Wiener Boerse
| UCB | End-of-day quote | |
|
Borsa Italiana
| 4UCB | End-of-day quote |
Last Transcript: UCB
| 1 day | -1.66% | ||
| 1 week | -6.30% | ||
| Current month | -2.05% | ||
| 1 month | -4.61% | ||
| 3 months | -22.58% | ||
| 6 months | -24.05% | ||
| Current year | -15.80% |
| 1 week | 200.2 |  | 215.7 |
| 1 month | 200.2 | | 217.1 |
| Current year | 200.2 | | 289.5 |
| 1 year | 200.2 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 01/07/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/1/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/1/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 15/1/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.66% | -6.30% | -20.28% | +159.69% | 43.84B | |
| +0.02% | -3.41% | +36.11% | +115.09% | 1,019B | |
| -1.21% | -6.74% | +34.08% | +62.64% | 617B | |
| +1.12% | +0.54% | +13.62% | +79.94% | 464B | |
| -3.30% | -6.21% | +56.45% | +36.58% | 356B | |
| +0.93% | -3.16% | +21.65% | +43.02% | 333B | |
| +0.12% | -2.77% | +10.70% | +32.97% | 267B | |
| -0.89% | -6.28% | -7.00% | +8.01% | 244B | |
| -0.01% | -2.81% | +35.28% | +51.82% | 218B | |
| -0.08% | -4.17% | +28.34% | +93.51% | 179B | |
| Average | -0.08% | -3.66% | +20.90% | +68.33% | 374.1B | |
| Weighted average by Cap. | +0.26% | -3.55% | +27.93% | +71.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.66B 9.72B 8.07B 7.35B 13.85B 936B 13.93B 97.51B 37.91B 477B 36.47B 35.68B 1,534B | 9.61B 10.78B 8.96B 8.15B 15.37B 1,038B 15.46B 108B 42.06B 529B 40.46B 39.58B 1,702B |
| Net income | 1.93B 2.16B 1.8B 1.64B 3.08B 208B 3.1B 21.71B 8.44B 106B 8.12B 7.94B 342B | 2.3B 2.58B 2.14B 1.95B 3.67B 248B 3.7B 25.87B 10.06B 127B 9.67B 9.46B 407B |
| Net Debt | 413M 463M 385M 350M 660M 44.61B 664M 4.65B 1.81B 22.74B 1.74B 1.7B 73.11B | -1.7B -1.9B -1.58B -1.44B -2.71B -183B -2.73B -19.09B -7.42B -93.43B -7.14B -6.98B -300B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/10/26 | €200.90 | -1.66% | 159,633 |
| 02/10/26 | €204.30 | +1.49% | 176,155 |
| 01/10/26 | €201.30 | -1.85% | 237,472 |
| 30/09/26 | €205.10 | -0.82% | 302,223 |
| 29/09/26 | €206.80 | -2.68% | 358,447 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
